Paul Craddy is looking forward to attending the NICE Meta tool training course tomorrow.

Paul Craddy is looking forward to attending the NICE Meta tool training course tomorrow.

NICE has recently developed a META (MedTech Early Technical Assessment) tool, to support MedTech manufacturers in the identification of potential evidence gaps, that can hinder a NICE assessment. The outputs of the META tool will help you be able to develop an understanding of the evidence needed to demonstrate your product’s value to the NHS and identify evidence gaps that may delay patient access for your product. Find out more information as to how Remap Consulting can help your organisation here

By |2019-04-01T12:09:15+00:00April 1st, 2019|News|0 Comments

Remap Consulting team supporting the East Cheshire Hospice

Remap Consulting are extremely proud to have supported the East Cheshire Hospice by wrapping over 400 collection tins with their new branding.

East Cheshire Hospice provide compassionate palliative care to local adults facing life-limiting illnesses and offer support to their families and relies on the kind generosity of the local community to help raise the £7,500 needed a day.

As a member of the 500 Club, Remap Consulting is part of a network of forward thinking, community engaged and socially responsible companies who donate or raise at least £500 per year, to support the East Cheshire Hospice. Corporate Fundraising is an essential part of helping raise their daily running costs, please help us achieve our target by donating via our just giving page

Supporting the East Cheshire Hospice

Our regular commitment will enable the Hospice to plan services and secure the future of […]

By |2019-04-01T10:13:05+00:00March 29th, 2019|News|0 Comments

Remap team members proud to be supporting the East Cheshire Hospice

Remap Consulting team proud to be supporting East Cheshire Hospice raise much needs funds today by wrapping branded collection tins and buckets

If you would like to help them raise funds for this extremely worthy cause, please click here

By |2019-03-29T09:35:21+00:00March 29th, 2019|News|0 Comments

Canadian government to make prescription drugs more affordable

National pharmacare to make prescription drugs more accessible and affordable

Canadians pay too much for prescription drugs – and that means far too many go without the medicine they need. With Budget 2019, the Government of Canada is taking important first steps on implementing national pharmacare, to make prescription drugs more accessible and affordable to more Canadians.

The Prime Minister, Justin Trudeau, today visited Halifax, Nova Scotia to highlight the Government of Canada’s plan to move forward with important measures that will lay the foundation for national pharmacare.

Read the full article here

This document is also available at

SOURCE Prime Minister’s Office

By |2019-03-29T07:50:24+00:00March 29th, 2019|News|0 Comments

National body to ensure CCG decisions for patient access to treatments are consistent

There needs to be a national body to examine CCG decisions ensuring that patient access to treatments is consistent across the country according to a report published this week by the Medical Technology Group (MTG) which members consist of patient groups, charities and medical device manufacturers.

Following a series of FOI requests to CCGs, MTG said a number of CCGs are currently restricting access to procedures such as cataract surgery, hernia repair, hip and knee replacements, and glucose monitoring.

As many as 104 of the 195 CCGs in England list cataract surgery among the procedure deemed to have ‘limited clinical value’, MTG found, despite NICE guidance in 2017 concluding that the procedure is cost-effective, as it has a ‘high success rate improving visual function, with low morbidity and mortality’.

Read the full article courtesy of Valeria Fiore here



By |2019-03-26T12:44:54+00:00March 26th, 2019|News|0 Comments

Paul Craddy is presenting at Manchester Metropolitan University tomorrow

Paul Craddy will be presenting to Manchester Metropolitan University students tomorrow on the opportunities and challenges of gaining commercial access for precision medicines.

Paul presenting at Manchester Metropolitan University

By |2019-03-20T15:43:22+00:00March 25th, 2019|Careers, News|0 Comments

Remap team members to run Manchester 10k for East Cheshire Hospice

Some members of the Remap Consulting team will be running the Manchester 10k on the 19th May and are raising money for the East Cheshire Hospice. If you would like to help them raise funds for this extremely worthy cause, please click here

Manchester 10k

By |2019-03-20T15:44:30+00:00March 21st, 2019|News|0 Comments

NICE approve Almirall’s Ilumetri, UCB’s Cimzia

The National Institute for Health and Care Excellence (NICE) has recommended Almirall’s Ilumetri and UCB’s Cimzia as treatment options for severe plaque psoriasis in final draft guidelines.

Initially NICE rejected Illumetri for not being cost-effective, but a new negotiated price submitted by the company means that it can now be offered as an alternative for patients who are unable to take systemic non-biological treatments.

Read the full article written by Anna Smith here.

By |2019-03-20T15:48:22+00:00March 20th, 2019|News|0 Comments

NICE suggests industry and payers need to do more to align on value, evidence and price

England’s cost effectiveness watchdog NICE can shift away from its current default of starting with a ‘no’ to new drugs, and then negotiating a deal with pharma companies – but requires greater co-operation from industry, according to its chief executive.

Speaking at the international pharma conference eyeforpharma Barcelona last week, NICE’s chief executive Sir Andrew Dillon struck a conciliatory note with his audience, making it clear he understood the sector’s need to provide shareholders with a return on investment on novel medicines.

However, he cautioned that industry, healthcare payers and health technology assessment (HTA) authorities like NICE needed to do more to achieve ‘alignment’ on value, evidence and price for the sake of patients.

Read the full article by Andrew MConaghie here.

By |2019-03-19T10:49:18+00:00March 19th, 2019|News|0 Comments

SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma

Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.

The Scottish Medicines Consortium (SMC) said it could not accept Kymriah (tisagenlecleucel) for adult patients with diffuse B cell lymphoma who have relapsed or not responded after two previous lines of treatment.

Despite being considered under the PACE process, the committee did not recommend tisagenlecleucel “because of uncertainties in the company’s evidence around its long term benefits”.

Read the full article by Selina McKee here.

By |2019-03-20T15:50:19+00:00March 15th, 2019|News|0 Comments